Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Donaperminogene seltoplasmid by Helixmith for Intermittent Claudication: Likelihood of Approval
Donaperminogene seltoplasmid is under clinical development by Helixmith and currently in Phase II for Intermittent Claudication. According to GlobalData, Phase...